If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
I said ‘delayed’ as although technically anything in Q1 is on time, if they have results which they do, but haven’t released them yet it feels like a delay.
Abs you say P3, but is this Sprinter or Activ 2… both are P3, but if positive sprinter which we hope is announced any day now, will that be enough for an EUA, or do you think it is Activ 2 which will have to be successful for the EUA as that is US’s own phase 3 trial.
Do people think this is because of Sprinter results or to do with Activ 2? Or kind of both, knowing the sprinter results means they can predict the Activ 2 results.
Also what’s the advantage of being based in US? Tax benefit, American company so better image to the public or just easier with logistics?
Part of me also wonders with this ‘delayed’ sprinter RNS, is it due to dotting I’s and crossing T’s regarding what comes next with orders for the drug. Mother of all RNS (Sprinter results and EUA) would be life changing for us share holders.
I have a little invested in this company, not been following it too closely. But these divi people are suggesting seem crazy… am I missing something. Why would the div be multiples of the current SP? I won’t complain if it is!
The RNS is good but is this translating to cash coming in for the company or trials being successful for the drug, no.
So if you’re wanting a big rise you need one of those. Until then even good news may not see a rise in the SP, but make no mistake, the news is good and the company is heading in the right direction.
Don’t like bringing up other companies but look at 4D, positive Rns, company going in right direction, but look at the SP.
I somewhat agree. FTSE AIM companies often have a SP not truly a fair reflection to the companies real value. The seller and loss of faith in this company is driving the price down. But nothing has changed and this company deserves a much much higher SP, I have no doubts one day this SP will get to where it deserves. But truly we need more results and orders to achieve that, so until that day comes it may be a bumpy ride. I’m not putting loads into 4D, but I am buying as it goes down and accepting this may be a 3 year wait until I see the returns I want.
From my little experience with the world of investing, every RNS always tries to sound better than it is. Even if P3 is unsuccessful I suspect it will be spun out as still positive, optimistic in regards to looking forward to COPD and asthma application.
I do like to read RNS results a few times to make sure I understand it, I then look at this very board to make sure other people are reading what I am reading!
Tyla, there is fair risk with this investment. But the reward is potentially exceptional. Can’t say I know of any other investments right now with this potential. Hence why so much of my portfolio is tied up here.
I understand funds have to balance. Just think so close to results they must be aware of the risk reward of this share. Maybe they are over exposed, I know I am. But it just seems a risk worth taking.
The company on paper has a lot of potential. OS selling causing selling pressure so presumably the price to drop. No bad news from the company so in theory no reason this shouldn’t get back to previous highs. If this gets to 30p I’ll buy some more, but for now I’m holding. This will likely take months/years to cover but I see no reason why it shouldn’t.
Buy low sell high.
On this paper though : https://pubmed.ncbi.nlm.nih.gov/34672949/
Can someone explain to me the interpretation of these findings? We haven’t finished phase 3 yet so why is the following stated?
Interpretation: Interferon beta-1a plus remdesivir was not superior to remdesivir alone in hospitalised patients with COVID-19 pneumonia. Patients who required high-flow oxygen at baseline had worse outcomes after treatment with interferon beta-1a compared with those given placebo.
New variants, new respiratory viruses… I sometimes wonder though, if you’re on this forum and invested in their company, you likely have done your research. You would have to be smooth brained to sell after reading some of these posts on here and not looking into it and applying your own DD.